GSK Ends Pact with Vir For New COVID Treatments

Although Flu And Respiratory Collaboration Continues

Its Xevudy partner GSK is pulling out but Vir is going to carry on looking for new COVID-19 solutions independently, or with other partners.

COVID-19 SARS,Coronaviridae , SARS-CoV, SARSCoV, virus 2020 , MERS-CoV ,chinese virus 2019-nCoV
• Source: Shutterstock

Vir Biotechnology, Inc. is planning to go it alone or work with new partners to advance next-generation therapies for COVID-19 and other potential coronavirus outbreaks after GSK plc decided that its research priorities lie elsewhere.

The San Francisco-based biotech has revealed that its research collaboration agreement

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip